The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
ChimeriVax-West Nile Virus Live-Attenuated Vaccine: Preclinical Evaluation of Safety, Immunogenicity, and Efficacy
Open accessAbstract
The availability of ChimeriVax vaccine technology for delivery of flavivirus protective antigens at the time West Nile (WN) virus was first detected in North America in 1999 contributed to the rapid development of the vaccine candidate against WN virus described here. ChimeriVax-Japanese encephalitis (JE), the first live- attenuated vaccine developed with this technology has successfully undergone phase I and II clinical trials. The ChimeriVax technology utilizes yellow fever virus (YF) 17D vaccine strain capsid and nonstructural genes to deliver the envelope gene of other flaviviruses as live-attenuated chimeric viruses. Amino acid sequence homology between the envelope protein (E) of JE and WN viruses facilitated targeting attenuating mutation sites to develop the WN vaccine. Here we discuss preclinical studies with the ChimeriVax-WN virus in mice and macaques. ChimeriVax-WN virus vaccine is less neurovirulent than the commercial YF 17D vaccine in mice and nonhuman primates. Attenuation of the virus is determined by the chimeric nature of the construct containing attenuating mutations in the YF 17D virus backbone and three point mutations introduced to alter residues 107, 316, and 440 in the WN virus E protein gene. The safety, immunogenicity, and efficacy of the ChimeriVax-WN 02 vaccine in the macaque model indicate the vaccine candidate is expected to be safe and immunogenic for humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lanciotti, R. S., Roehrig, J. T., Deubel, V., Smith, J., Parker, M., Steele, K., Crise, B., Volpe, K. E., Crabtree, M. B., Scherret, J. H., et al. (1999) · Science · doi:10.1126/science.286.5448.2333 · Cited by 1,593
Cited by
Querec, T., Bennouna, S., Alkan, S., Laouar, Y., Gorden, K., Flavell, R., Akira, S., Ahmed, R., & Pulendran, B. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051720 · Cited by 552
Monath, T. P. (2005) · Expert Review of Vaccines · doi:10.1586/14760584.4.4.553 · Cited by 467
Self-citationWest Nile virus neuroinvasive disease
Davis, L. E., DeBiasi, R., Goade, D. E., Haaland, K. Y., Harrington, J. A., Harnar, J. B., Pergam, S. A., King, M. K., DeMasters, B. K., & Tyler, K. L. (2006) · Annals of Neurology · doi:10.1002/ana.20959 · Cited by 388
Samuel, M. A., & Diamond, M. S. (2006) · Journal of Virology · doi:10.1128/jvi.01122-06 · Cited by 352
Kramer, L. D., Li, J., & Shi, P.-Y. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70030-3 · Cited by 318
Metadata
- Authors
- Arroyo, J., Miller, C., Catalan, J., Myers, G. A., Ratterree, M. S., Trent, D. W., & Monath, T. P.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2004-11-15
- Volume
- 78
- Issue
- 22
- Pages
- 12497-12507
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- OpenAlex
- W1990720325
- Cited by
- 213
- References
- 1
- FWCI
- 14.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ChimeriVax-West Nile Virus Live-Attenuated Vaccine: Preclinical Evaluation of Safety, Immunogenicity, and Efficacy. https://app.cochat.ai/papers/10.1128/jvi.78.22.12497-12507.2004
- The paper
- Arroyo, J., Miller, C., Catalan, J., Myers, G. A., Ratterree, M. S., Trent, D. W., & Monath, T. P. (2004). ChimeriVax-West Nile Virus Live-Attenuated Vaccine: Preclinical Evaluation of Safety, Immunogenicity, and Efficacy. Journal of Virology. https://doi.org/10.1128/jvi.78.22.12497-12507.2004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.